Combining whole genome miRNA/mRNA sequencing, bioinformatics and network biology, miRNAs/their target network involved in chemoresistance will be identified, and targeted to enhance the chemoresponse
of TNBC models.
The company's flagship product, the ChemoFx Chemoresponse
Marker(ChemoFx), helps improve patient outcomes by supporting physicians in the selection of effective treatments for women with gynecologic cancer.
Effects of liquid growth versus plate growth of Caenorhabditis elegans on chemoresponse
to pathogenic bacteria.
57) Induction chemotherapy before definitive surgery allows us to assess the chemoresponse
in resected specimens, which has some prognostic significance and has a role in selection of agents for continuation chemotherapy.
1:20-1:40 pm Bin Guo * BCL-G IN APOPTOSIS AND CHEMORESPONSE
A Systematic Evaluation of Multi-Gene Predictors for the Pathological Response of Breast Cancer Patients to Chemotherapy examined 42 breast cancer cell lines by using the ChemoFx in-vitro chemoresponse
test after treatment with two widely used standard combination chemotherapies for breast cancer.
The study, titled, Multigene Predictors Developed on Breast Cancer Cell Lines to Predict Patient Chemotherapy Response: A Validation Study on the NSABP B-27 Trial, combined the genomic profiles of cell lines with their in vitro chemoresponse
data to identify genes whose expression was associated with drug response.
PITTSBURGH -- In Vitro Chemoresponse
Assessment of Optimally and Sub-Optimally Debulked Primary Ovarian Cancer,a studysubmitted by Dr.
In a study conducted between Precision, US Oncology, and MD Anderson Cancer Center, multigene predictors (MGPs) of response to multidrug chemotherapy regimens were developed by correlating in vitro chemoresponse
(ChemoFx) microarray gene expression data from 39 different breast cancer cell lines.
Grigsby and titled, In Vitro Chemoresponse
Analysis and Clinical Outcomes in Cervical Cancer.
The publication, titled, "Impact of a Chemoresponse
Assay on Treatment Costs for Recurrent Ovarian Cancer," evaluated the net cost savings associated with the use of the ChemoFx drug response marker to aid therapeutic decisions in the setting of recurrent ovarian cancer, and reveals a possible cost savings of $15,600 to $24,800.
In Vitro Chemoresponse
in Metachronous Pairs of Gynecologic Cancers, recently presented in poster form at the British Gynaecological Cancer Society (BGCS) Annual Meeting held July 5-6, 2012, was conducted by Dr.